Growth and apoptosis of human natural killer cell neoplasms: Role of interleukin-2/15 signaling

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1023-1031

  Yamasaki, Satoshi ^a   Maeda, Motoi ^b   Ohshima, Koichi ^c   Kikuchi, Masahiro ^c   Otsuka, Teruhisa ^a   Harada, Mine ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

AICD; hematopoietic stem cell transplantation; HSCT; IL; IL 15 receptor ; IL 15R ; IL 2 receptor ; IL 2 15 receptor ; IL 2 15 receptor ; IL 2 15R ; IL 2 15R ; IL 2R ; interleukin; natural killer; NK

Indexed keywords

INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR BETA; PROTEIN BCL 2; PROTEIN BCL XL; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MALE; NATURAL KILLER CELL NEOPLASM; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-15; RECEPTORS, INTERLEUKIN-2; SIGNAL TRANSDUCTION;

EID: 3843099310     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.02.006     Document Type: Article

References (40)

1. Imamura N., Kusunoki Y., Kawa-Ha K., Yumura K., Hara J., Oda K., et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Br. J. Haematol. 75:1990;49-59
2. Chan J.K., Sin V.C., Wong K.F., Ng C.S., Tsang W.Y., Chan C.H., et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 89:1997;4501-4513
3. Koita H., Suzumiya J., Ohshima K., Takeshita M., Kimura N., Kikuchi M., et al. Lymphoblastic lymphoma expressing natural killer cell phenotype with involvement of the mediastinum and nasal cavity. Am. J. Surg. Pathol. 21:1997;242-248
4. Kwong Y.L., Chan A.C., Liang R., Chiang A.K., Chim C.S., Chan T.K., et al. CD56 + NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol. 97:1997;821-829
5. Li C.C., Tien H.F., Tang J.L., Yao M., Chen Y.C., Su I.J., et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 100:2004;366-375
6. Jaffe ES, Ralfkiaer E. Mature T-cell, NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumors of Haematopoietic and Lymphoid Tissue. Lyon (France): IARC Press; 2001. p. 214-5.
7. Chiang A.K.S., Srivastava G., Lau P.W.F., Ho F.C.S. Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin. Hum. Pathol. 27:1996;701-707
8. Liang R., Todd D., Chan T.K., Chiu E., Lie A., Kwong Y.L., et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J. Clin. Oncol. 13:1995;666-670
9. Cheung M.M., Chan J.K., Lau W.H., Foo W., Chan P.T., Ng C.S., et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J. Clin. Oncol. 16:1998;70-77
10. Bower C.P., Standen G.R., Pawade J., Knechtli C.J., Kennedy C.T. Cutaneous presentation of steroid responsive blastoid natural killer cell lymphoma. Br. J. Dermatol. 142:2000;1017-1020
11. + non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood. 89:1997;2966-2974
12. Takenaka K., Shinagawa K., Maeda Y., Makita M., Kozuka T., Ashiba A., et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk. Lymphoma. 42:2001;1297-1303
13. Burton J.D., Bamford R.N., Peters C., Grant A.J., Kurys G., Goldman C.K., et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;4935-4939
14. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1994;1395-1403
15. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 264:1994;965-968
16. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. J. Eur. Mol. Biol. Org. 13:1994;2822-2830
17. Giri J.G., Kumaki S., Ahdieh M., Friend D.J., Loomis A., Shanebeck K., et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. J. Eur. Mol. Biol. Org. 14:1995;3654-3663
18. Carson W.E., Fehniger T.A., Haldar S., Eckhert K., Lindemann M.J., Lai C.F., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99:1997;937-943
19. Lodolce J.P., Boone D.L., Chai S., Swain R.E., Dassopoulos T., Trettin S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 9:1998;669-676
20. Fehniger T.A., Suzuki K., Ponnappan A., VanDeusen J.B., Cooper M.A., Florea S.M., et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193:2001;219-231
21. Waldmann T.A. The IL-2/IL-15 receptor systems: targets for immunotherapy. J. Clin. Immunol. 22:2002;51-56
22. Bamford R.N., Battiata A.P., Burton J.D., Sharma H., Waldmann T.A. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2897-2902
23. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 8:1994;652-658
24. Yagita M., Huang C.L., Umehara H., Matsuo Y., Tabata R., Miyake M., et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 14:2000;922-930
25. Nagata H., Konno A., Kimura N., Zhang Y., Kimura M., Demachi A., et al. Characterization of novel natural killer (NK)-cell and γδ T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus. Blood. 97:2001;708-713
26. Kagami Y., Nakamura S., Suzuki R., Iida S., Yatabe Y., Okada Y., et al. Establishment of an IL-2-stimulated cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3ε+, CD56+ phenotype and associated with the Epstein-Barr virus. Br. J. Haematol. 103:1998;669-677
27. Matsuo Y., Drexler H.G., Takeuchi M., Tanaka M., Orita K. Establishment of the T-cell large granular lymphocyte leukemia cell line MOTN-1 carrying natural killer-cell antigens. Leuk. Res. 26:2002;873-879
28. Ohshima K., Suzumiya J., Sugihara M., Kanda M., Shimazaki K., Kawasaki C., et al. Clinical, immunohistochemical and phenotypic features of aggressive nodal cytotoxic lymphomas, including alpha/beta, gamma/delta T-cell and natural killer cell types. Virchows Arch. 435:1999;92-100
29. Bulfone-Paus S., Durkop H., Paus R., Krause H., Pohl T., Onu A. Differential regulation of human T lymphoblast function by IL-2 and IL-15. Cytokine. 9:1997;507-513
30. Raff T., van der G., Endemann D., Wiederholt T., Paul M. Design and testing of β-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechnique. 23:1997;456-460
31. Ruckert R., Asadullah K., Seifert M., Budagian V.M., Arnold R., Trombotto C., et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis. J. Immunol. 165:2000;2240-2250
32. Kurowska M., Rudnicka W., Kontny E., Janicka I., Chorazy M., Kowalczewski J., et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J. Immunol. 169:2002;1760-1767
33. Neely G.G., Robbins S.M., Amankwah E.K., Epelman S., Wong H., Spurrell J.C., et al. Lipopolysaccharide-stimulated or granulocyte-macrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J. Immunol. 167:2001;5011-5017
34. Mrozek E., Anderson P., Caligiuri M.A. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 184:1996;325-336
35. Leclercq G., Debacker V., de Smedt M., Plum J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 184:1996;325-336
36. Murray A.M., Simm B., Beagley K.W. Cytokine gene expression in murine fetal intestine: potential for extrathymic T cell development. Cytokine. 10:1998;337-345
37. Koka R., Burkett P.R., Chien M., Chai S., Chan F., Lodolce J.P., et al. Interleukin (IL)-15R{alpha}-deficient natural killer cells survive in normal but not IL-15R{alpha}-deficient mice. J. Exp. Med. 197:2003;977-984
38. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15R-alpha recycles and presents IL-15 in trans to neighboring cells. Immunity. 17:2002;537-547
39. Minagawa M., Watanabe H., Miyaji C., Tomiyama K., Shimura H., Ito A., et al. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice. J. Immunol. 169:2002;4153-4160
40. Masuda A., Matsuguchi T., Yamaki K., Hayakawa T., Yoshikai Y. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression. J. Biol. Chem. 276:2001;26107-26113